EGFR inhibitors such as gefitinib and laptinib have shown efficacy in other malignancies, but only moderate success in breast cancer, suggesting that an improved method of patient selection is required to identify those who would benefit the most. The gene discussed is EGFR; the disease is breast carcinoma.